论文部分内容阅读
目的:探讨小鼠肾包膜下移植肿瘤药敏测定(SRCA)在复发耐药NHL治疗中的作用.方法:对25例CHOP方案化疗后出现复发耐药的NHL病人进行了SRCA药敏测定,并依据SRCA结果进行化疗.结果:NHL肿瘤细胞在小鼠肾包膜下能够快速生长,移植成功率100%;复发耐药NHL对CTX、VCR、ADM表现为耐药,而对VP_(16)、MTX、DDP敏感性较高,其中对VP_(16)的敏感性显著高于CTX和VCR(P<0.05);依据药敏结果化疗,25例病人6例CR、13例PR,总有效率76%;其中21例接受由VP_(16)、MTX、DDP和强的松组成的方案治疗,6例CR,11例PR,有效率达81%.结论:NHL适宜用SRCA法进行药敏测定;复发耐药NHL的治疗可以VP_(16)、MTX和DDP为基础;化疗前进行SRCA药敏测定,能够减少用药盲目性,提高有效率.
OBJECTIVE: To investigate the role of mouse subcapsular transplant tumor susceptibility testing (SRCA) in the treatment of relapsed drug-resistant NHL. Methods: SRCA susceptibility testing was performed on 25 patients with relapse-resistance NHL after CHOP chemotherapy. The chemotherapy was performed according to the SRCA results. Results: NHL tumor cells grew rapidly under the renal capsule of mice, the success rate of transplantation was 100%; relapsed resistant NHL showed resistance to CTX, VCR, and ADM, but to VP_ (16) The sensitivity of MTX and DDP was higher, and the sensitivity to VP_(16) was significantly higher than that of CTX and VCR (P<0.05). According to the drug sensitivity results of chemotherapy, 25 patients had CR in 6 cases and PR in 13 cases. 76%; 21 of them received the regimen consisting of VP 16 , MTX, DDP and prednisone, 6 CR and 11 PR, and the effective rate was 81%. Conclusion: NHL is suitable for susceptibility testing with SRCA method. The treatment of relapsed resistant NHL can be based on VP_(16), MTX and DDP; SRCA susceptibility testing before chemotherapy can reduce the blindness of medication and increase the efficiency.